國家衛生研究院 NHRI:Item 3990099045/10405
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 859711      線上人數 : 778
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/10405


    題名: Sequential use of everolimus and sunitinib in treating WHO grade 1 and 2 pancreatic neuroendocrine tumors-retrospective multi-center study in Taiwan
    作者: Liu, CT;Chen, LT;Chen, YY;Chen, JS;Su, YL;Chou, WC;Lu, CH;Ku, FC;Chen, MH;Shan, YS
    貢獻者: National Institute of Cancer Research
    摘要: Background: There are at least four different systemic treatments for grade 1 and 2 advanced pancreatic neuroendocrine tumors (pNETS), including chemotherapy, somatostatin analogues, sunitinib and everolimus. Sequential sunitinib and everolimus in renal cell carcinoma have led to an improvement in overall survival. Theoretically, this is believed to occur in pNETS but not been proved, yet. The purpose of this retrospective study was to compare outcomes for patients with pNETS receiving two targeted therapies, everolimus and sunitinib, sequentially. Methods: This is a retrospective multi-center registration study. The primary objective was to assess progression-free survival (PFS) of front-line everolimus compared with front-line sunitinib. Secondary objectives was safety profile of both agents. Results: From Feb. 1st. 2008 to Oct. 31th. 2014, twenty-four patients were included in seven medical centers in Taiwan. Overall median age was 52.6 years, and most patients were women (58.3%). Median PFS was 14.2 months with front line everolimus, 4.9 months with front line sunitinib (hazard ratio [HR], 0.34; 95% confidence interval (CI), 0.13 to 0.90, p = 0.08). After discontinuing from front line targeted therapy, median PFS was 13.0 months with everolimus in later line, 7.2 months with sunitinib in later line (HR, 1.79; 95% CI, 0.65 to 4.94, p = 0.64). There is 36.5% of patients discontinued sunitinib due to adverse events, no matter front or later line, compared to 6.7% patients while receiving everolimus. Conclusions: Sequential use of everolimus and sunitinib in treating patient with advanced pNETS may be an option, but prospective and randomized trials that seek for the sequence of targeted therapies are highly needed.
    日期: 2016-12
    關聯: Annals of Oncology. 2016 Dec;27(Suppl. 9):Meeting Abstract 420P.
    Link to: http://dx.doi.org/10.1093/annonc/mdw590.006
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0923-7534&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000393980600419
    顯示於類別:[陳立宗] 會議論文/會議摘要

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI000393980600419.pdf72KbAdobe PDF217檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋